Immunoprevention for High-risk Lung Lesions — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Immunoprevention for High-risk Lung Lesions — Stella

Accepting patients

Back to High-risk Lung Nodules trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

Trial locations(1 site)

United States

Icahn School of Medicine at Mount Sinai, New York, New York

Key details

Phase

Small group testing

Sponsor

Robert Samstein

Collaborators

Cantargia AB

Enrollment target

~59 participants

Started

April 2026

Primary completion

December 2027

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov